Previous Page  3 / 29 Next Page
Information
Show Menu
Previous Page 3 / 29 Next Page
Page Background

Notes:

Page 26

Bio Summit & Molecular Biology 2016

October 10-12, 2016

Volume 6, Issue 6(Suppl)

J Biotechnol Biomater

ISSN: 2155-952X JBTBM, an open access journal

conferenceseries

.com

October 10-12, 2016 Dubai, UAE

2

nd

World Congress on

Bio Summit & Molecular Biology Expo

Saif Aldeen Saleh Al Ryalat, J Biotechnol Biomater 2016, 6:6(Suppl)

http://dx.doi.org/10.4172/2155-952X.C1.061

CRISPR-Cas 9 system; the new tool to design our own bio-production system

Saif Aldeen Saleh Al Ryalat

The University of Jordan, Jordan

I

n 2012, Doctor Doudna and her colleagues generated a new discovery that would reduce the time and work needed to

edit genomic DNA, it is Cas9 protein that can be found in Streptococcus bacteria CRISPR immune system. CRISPR-Cas 9

introduced as a tool for sequence-specific Double Strand Breakage (DSB) with low relative cost and high specificity and success

rates. The capability of this system to perform targeted, highly efficient alterations of genome sequence and gene expression

will undoubtedly transform biological research and spur the development of novel molecular therapeutics for human disease

with significantly lower costs. The days where kilograms of animal and plant tissues or large volumes of biological fluids were

needed for the purification of small amounts of a given protein are almost gone, we now have the ability to express and purify

the desired recombinant protein in a large quantity with relatively low cost. In our speech, we will discuss how to design our

own bio-production system by integrating all new advances in the field of genetic engineering, using E. coli bacteria as a

prototype host of protein production.

Biography

Saif Aldeen Saleh Al Ryalat is a leading Researcher in several aspects of medicine, including genetic engineering and neurology. He is working on a project to

design a bio-production system to design aglycosylated antibodies that can replace monoclonal glycosylated antibodies that are used in several neurological

diseases (relatively high cost). He is also a peer Reviewer for several journals and a Researcher with several high impact publications. He is currently at School of

Medicine at The University of Jordan where he had several honors and certificates.

saifryalat@yahoo.com